EMEA-001638-PIP01-14-M02
Table of contents
Key facts
| Invented name |
Tecentriq
|
| Active substance |
atezolizumab
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0207/2019
|
| PIP number |
EMEA-001638-PIP01-14-M02
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Roche Registration GmbH
Tel. +41 616879411 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-001638-PIP01-14-M02
|
| Compliance opinion date |
20/09/2019
|
| Compliance outcome |
positive
|